In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Promethera Biosciences SA NV

www.promethera.com

Latest From Promethera Biosciences SA NV

Venture Funding Deals: Takeda's Phathom Raises $140m In Crossover Round For GERD Program

AgomAb, CinCor and Confo Therapeutics secure Series A financing, while AlloVir closes a $121m Series B and more venture financing in April and May.

Deals Financing

Finance Watch: Q1 Numbers Suggest A Brisk VC Deal Pace For Cell And Gene Therapies In 2019

An Alliance for Regenerative Medicine (ARM) report shows big Q1 numbers for venture capital and partnership deals. Also, mid-May VC deals surge globally across therapeutic areas, Biogen pushes back against a bargain-hunting investor and recent public company financings.

Financing Regenerative Medicine

Finance Watch: A One-Time Treatment For Heart Disease? Verve Raises $58.5m To Give It A Try

Private Company Edition: With academic muscle, Google cash and nanoparticles, and various CRISPR licenses, Verve will develop gene-editing therapies for coronary heart disease prevention. Also, Vividion raises an $82m series B and two Belgian companies bring in $77.8m in VC cash.

Financing StartUps and SMEs

Asian Investors Bankroll €40m Promethera Biosciences Series D

Liver disease-focused Belgian cell therapy biotech Promethera Biosciences closes a €39.7m ($44.4m) Series D round co-led by new Japanese investors Itochu Corporation and Shinsei Capital Partners. Asian investors now own about 44% of company.

Commercial Financing
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Therapeutic Areas
  • Hepatic (Liver)
  • Alias(es)
  • Promethera Biosciences
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Benelux
          • Belgium
  • Parent & Subsidiaries
  • Promethera Biosciences SA NV
  • Senior Management
  • John Tchelingerian, PhD, Pres. & CEO
    Mutsuki Takano, CFO
    Etienne Sokal, MD, PhD, CMO & CSO
    Henrik L Luessen, PhD, CBO
  • Contact Info
  • Promethera Biosciences SA NV
    Phone: (32) (0)10 39 43 00
    Rue Granbonpré, 11
    Watson & Crick
    Mont-Saint-Guibert, B-1435
    Belgium
Advertisement
Advertisement
UsernamePublicRestriction

Register